A Novel Treatment for Aphasia and Apraxia of Speech : Measurement of Outcomes (AA: MoO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01979159|
Recruitment Status : Active, not recruiting
First Posted : November 8, 2013
Last Update Posted : September 25, 2017
In order to determine if speech-language therapy has positive effect, reliable measurement tools are required to document outcomes. Currently, there is very limited information concerning the measurement of changes in speech production as a result of treatment for acquired apraxia of speech and aphasia. This study will obtain information concerning the reliability of several speech production measures over time. Thirty persons with chronic aphasia and apraxia of speech will be asked to provide speech samples in response to commonly used assessment tools on three sampling occasions so that the stability of measurements may be examined.
After establishment of appropriate outcome measures, a small, pilot treatment study will be conducted with four participants. The participants will receive a new treatment for aphasia and acquired apraxia of speech and outcomes will be measured relative to speech and language production.
|Condition or disease||Intervention/treatment|
|Apraxia of Speech Aphasia||Behavioral: Combined Aphasia and Apraxia of Speech Treatment (CAAST)|
A single group, repeated measures design will be used to obtain repeated speech samples from 30 persons with chronic acquired apraxia of speech and aphasia. Speech samples will be elicited using commonly employed motor speech assessment protocols; an initial sample, a sample one week following the initial sample, and a sample at four weeks following the initial sample. The following measures will be obtained from the samples: percent consonants correct, percent fluent utterances, and duration of utterance. Stability of the measures will be examined.
After the preceding measures have been analyzed, a series of four, single-subject experimental designs will be conducted. Four participants with chronic aphasia and apraxia of speech will receive a new treatment for aphasia and apraxia of speech applied sequentially to two sets of experimental picture picture stimuli. Outcomes will be measured in terms of speech production (measures described above) as well as in terms of language production.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Novel Treatment for Aphasia and Apraxia of Speech: Measurement of Outcomes|
|Actual Study Start Date :||October 21, 2013|
|Primary Completion Date :||December 30, 2016|
|Estimated Study Completion Date :||December 29, 2017|
Experimental: Combined aphasia and apraxia of speech treatment (CAAST)
Administration of CAAST to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
Behavioral: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
Other Name: CAAST
- speech and language production [ Time Frame: Following completion of treatment; 3 sessions per week for 13-14 weeks ]production of connected speech/language in response to picture stimuli
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01979159
|United States, Utah|
|VA Salt Lake City Health Care System, Salt Lake City, UT|
|Salt Lake City, Utah, United States, 84148|
|Principal Investigator:||Julie L Wambaugh, PhD||VA Salt Lake City Health Care System, Salt Lake City, UT|